[PDF] Top 20 RIG-1 receptor expression in the pathology of Alzheimer’s disease
Has 10000 "RIG-1 receptor expression in the pathology of Alzheimer’s disease" found on our website. Below are the top 20 most common "RIG-1 receptor expression in the pathology of Alzheimer’s disease".
RIG-1 receptor expression in the pathology of Alzheimer’s disease
... TLRs, RIG-I-like receptors (RLR), NOD-like receptors (NLR), and C-type lectin re- ceptors ...(LGP2). RIG-1 recognizes relatively short dsRNA (up to 1 kb) whereas MDA5 detects long dsRNA (more ... See full document
9
Stem cell models of Alzheimer’s disease: progress and challenges
... Raja and colleagues used generated 3D organoids, using a protocol described by Kadoshima and colleagues, to investigate pathological processes in the absence of overexpression in cells from patients with APP duplica- ... See full document
17
Molecular Imaging of Alzheimer Disease Pathology
... 85. Barthel H, Luthardt J, Becker G, et al. Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and ... See full document
6
Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission?
... the pathology astrocytes undergo generalised atrophy and down-regulation of GFAP expression, which may indicate early compromise of astrocytic homeostatic functions ...astroglial expression of GFAP ... See full document
9
Modulation of inflammation in transgenic models of Alzheimer’s disease
... AD pathology whilst also increasing the expression of TNF-α and IL-10, suggesting an induction of a shift of activation of microglia towards the M2b state ...the expression of MyD88 in APP/PS1 mice ... See full document
13
Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort
... late-onset Alzheimer ’ s disease and related dis- orders (ADRD); however, the causes remain unknown, and no curative treatment is therefore ...’ s natural history, the surrogate markers of ... See full document
13
Glial activation and inflammation along the Alzheimer’s disease continuum
... Alzheimer’s disease (AD) may be described as a bio- logical continuum that includes the hallmark patho- logical processes of amyloid-beta (Aβ) dysmetabolism, formation of amyloid deposits (A), neurofibrillary ... See full document
13
Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies
... In the context of this study, we also sought to deter- mine whether enrichment strategies could improve the sensitivity to change over time of these ADAS-Cog vari- ants. Since the introduction of enrichment as part of ... See full document
13
Systematic reviews on behavioural and psychological symptoms in the older or demented population
... Behavioral Pathology in Alzheimer ’ s Disease scale; BPS: behavioural and psychological Symptoms; BPSD: behavioural and psychological symptoms of dementia; BSRS: Brief Behaviour Symptom Rating ... See full document
23
Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)
... AD pathology may indicate the stage of first subtle decline in cognitive brain function and corres- pond to stage 3 of preclinical AD ...’ s experience of this subtle cognitive dysfunction, which is still ... See full document
10
Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
... Elevated levels of CSF YKL-40 in early stages of AD have been demonstrated in two independent studies, but there are also contradictory data [28, 32, 40]. In our study, we confirmed that YKL-40 is elevated early in the ... See full document
8
BRIEF OVERVIEW ON ALZHEIMER`S DISEASE WITH RECENT TREATMENT
... In Alzheimer`s disease (AD), the pathology associated with glutamatergic neuron is not with glutamate itself but with the levels of pre and post synaptic glutamate ...glutamate ... See full document
9
Contribution of blood platelets to vascular pathology in Alzheimer's disease
... Abstract: Cerebral amyloid angiopathy (CAA) is a critical factor in the pathogenesis of Alzheimer’s disease (AD). In the clinical setting, nearly 98% AD patients have CAA, and 75% of these patients are rated as ... See full document
7
Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort
... ’ s disease (AD) is the leading cause of demen- tia worldwide and has been the target of clinical trials and intervention studies for many years ...the Alzheimer ’ s Disease Assessment ... See full document
13
Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
... Aβ42, tau, and ptau are important biomarkers for Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) levels of amyloid-beta (Aβ) and tau change before clin- ical symptoms of AD are observed. Aβ42 is decreased in ... See full document
9
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
... a registry of asymptomatic and symptomatic ADAD muta- tion carriers and their non-carrier siblings, who serve as a genetically similar control sample. DIAN participants are followed longitudinally by using clinical, ... See full document
7
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
... Likely owing to the challenges with active immunization described above, passive Aβ immunization programs are currently more numerous (Table 2). Eli Lilly and Com- pany has announced that a new phase 3 study in patients ... See full document
8
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review
... AD: Alzheimer ’ s disease; ADCS-ADL: Alzheimer ’ s Disease Cooperative Study/ Activities of Daily Living Inventory; ADCS-MCI-ADL-18: 18-item Alzheimer ’ s ... See full document
20
Cerebrovascular pathology in Down syndrome and Alzheimer disease
... developing Alzheimer disease (AD) with ...cerebrovascular pathology and compared in post mortem tissue from individuals with DS ( n = 32), sporadic AD ( n = 80) and controls ( n = ... See full document
9
Evidence that the presynaptic vesicle protein CSPalpha is a key player in synaptic degeneration and protection in Alzheimer’s disease
... p25 expression is downregulated in Alzheimer’s disease forebrain ...CSPalpha expression could be altered in Alzheimer’ s ...CSPalpha expression is reduced in hippocampus and STG ... See full document
12
Related subjects